

Navin Fluorine International

Estimate change

TP change

Rating change



Bloomberg	NFIL IN
Equity Shares (m)	51
M.Cap.(INRb)/(USDb)	390.4 / 4.1
52-Week Range (INR)	7936 / 4499
1, 6, 12 Rel. Per (%)	-1/25/47
12M Avg Val (INR M)	1322

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	33.1	43.8	52.8
EBITDA	10.8	14.4	16.9
PAT	6.7	9.1	10.6
EPS (INR)	130.5	177.5	207.2
EPS Gr. (%)	124.2	36.0	16.7
BV/Sh.(INR)	775.5	916.5	1,081.1

Ratios

Net D:E	0.3	0.2	0.2
RoE (%)	20.3	21.0	20.7
RoCE (%)	16.0	17.7	17.8
Payout (%)	20.6	20.6	20.6

Valuations

P/E (x)	58.4	42.9	36.8
P/BV (x)	9.8	8.3	7.0
EV/EBITDA (x)	37.1	27.8	23.7
Div. Yield (%)	0.3	0.5	0.6
FCF Yield (%)	1.0	0.8	1.2

Shareholding Pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	27.1	27.1	28.0
DII	28.5	27.6	28.7
FII	23.7	23.8	21.6
Others	20.7	21.5	21.7

FII includes depository receipts

CMP: INR7,610

TP: INR8,300 (+9%)

Neutral

Strong execution led by diversified growth engines

Operating performance beats estimates

- Navin Fluorine International (NFIL) delivered a robust performance in 1QFY27, with revenue growing 44% YoY, driven by broad-based strength across all business segments. High Performance Products (HPP)/Specialty Chemicals/CDMO revenues grew 33%/48%/82% YoY. EBITDA surged 73% YoY, led by operating leverage and improved pricing in the HPP segment.
- We remain positive on NFIL's outlook, supported by its diversified portfolio. We expect the HPP segment to sustain its growth momentum, aided by a favorable pricing environment and ongoing capacity expansions, while the Specialty Chemicals business is likely to maintain its strong trajectory, supported by robust order visibility and continued scale-up of existing molecules.
- Further we expect the CDMO business to sustain its momentum, supported by a balanced portfolio of late-stage, commercial, and early-stage molecules, along with the commercialization of Phase II cGMP-4 by 4QFY27.
- On the back of a strong 1QFY27 and improved EBITDA margin guidance, we increase our FY27/FY28 earnings estimates by 10%/13% and reiterate our **Neutral** rating on the stock with a TP of INR8,300 (40x FY28E EPS).

Robust 1QFY27 performance across all business segments

- NFIL reported revenue of INR10.5b (est. INR9.6), up 44% YoY, driven by growth across all three segments.
- Gross margin stood at 57% (down 60bp YoY), while EBITDA margin stood at 34.2% (28.5% in 1QFY26), driven by a favorable product mix and operational leverage.
- EBITDA stood at INR3.6b (est. INR3.2b), up 73% YoY, and adj. PAT grew 2.1x YoY to INR2.4b (est. INR1.9b)
- HPP revenue grew 33% YoY to INR5.4b, driven by higher volumes and improved realizations, while the pricing environment for HFC remained constructive.
- Specialty Chemicals revenue grew 48% YoY to INR3.3b, driven by 46% growth in the international business and strong scale-up across existing molecules.
- The CDMO business sustained its growth trajectory, with revenue growing 82% YoY to INR1.8b, driven by an increasing demand for existing molecules and continued deeper engagement with European CDMO majors.
- India/International revenue grew 50%/41% YoY in 1QFY27.

Highlights from the management commentary

- **Advanced materials:** NFIL has approved an INR900m capex to set up advanced materials capacity at Surat, with commissioning targeted by 2QFY28. The investment targets high-growth and margin sectors like semiconductors, data centers, electronics, and defense. The facility will scale up 4-5 customer-qualified products from lab to commercial production, while also supporting the development of a critical indigenous defense material in partnership with DRDO.

Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | **Nirvik Saini** (Nirvik.Saini@MotilalOswal.com)

Analyst: Swapnil Upadhyay (Swapnil.Upadhyayk@MotilalOswal.com) | **Yash Darak** (Yash.Darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **CDMO:** NFIL initiated phase 2 of cGMP4 capex of INR1.3b funded through internal accruals which is likely to get operationalized by 4QFY27. The expansion deepens engagement with European customers, with management targeting a 3x Asset T/O by FY29. The company is also moving up the value chain by expanding into API minus-one-stage manufacturing while progressing an early-phase molecule for a key customer.
- **Specialty chemicals:** Revenue grew 48% YoY during 1Q, driven by strong scale-up across existing molecules. MPP capacity expansion and Chemours project remain on track, supported by strong product pipeline. NFIL plans to pitch 4-5 new molecules in FY27, including three patented molecules, strengthening growth visibility and pricing resilience
- **HPP:** The 15kMTPA R32 capacity expansion remains on track for commissioning in 3QFY27. Management indicated that pricing environment for HFC continues to be constructive supported by demand-supply dynamics and rising interest for contractual offtakes in new capacities.

Valuation and view

- We believe NFIL is well-positioned to sustain its growth momentum, supported by the constructive pricing environment, growing international exposure, robust order visibility, and operational leverage, led by capacity ramp-up.
- The outlook is further supported by: 1) a strategic partnership with Chemours to foray into high-growth advanced materials (likely to be operational by 2QFY27), 2) planned investment for increasing the R32 capacity (likely to be operational by 3QFY27) and MPP debottlenecking for the specialty chemical plant at Dahej (targeted commissioning by 3QFY27), 3) the ramp-up of the AHF plant, and 4) the new advanced materials facility at Surat, to be commissioned by 2QFY28, targeting high-growth sectors and scaling customer-qualified products.
- We expect a CAGR of 26%/25%/26% in revenue/EBITDA/adj. PAT over FY26-28. The stock is trading at ~37x FY28E EPS of INR207 and ~24x FY28E EV/EBITDA. We value the company at 40x FY28E EPS to arrive at our TP of INR8,300, and **we reiterate our Neutral rating.**

Consolidated - Quarterly Snapshot

Y/E March	(INR m)											
	FY26				FY27E				FY26	FY27E	FY27	Var
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	(%)
Gross Sales	7,254	7,584	8,924	9,377	10,451	10,018	11,295	12,020	33,139	43,784	9,634	8
YoY Change (%)	38.5	46.3	47.2	33.8	44.1	32.1	26.6	28.2	41.1	32.1	32.8	
Total Expenditure	5,186	5,123	5,848	6,166	6,880	6,802	7,568	8,089	22,322	29,339	6,435	
Gross Margin (%)	57.6%	58.7%	58.8%	58.6%	57.0%	58.5%	59.0%	58.0%	58.5%	58.1%	58.0%	
EBITDA	2,068	2,462	3,076	3,212	3,571	3,216	3,727	3,930	10,817	14,444	3,198	12
Margin (%)	28.5	32.5	34.5	34.2	34.2	32.1	33.0	32.7	32.6	33.0	33.2	
Depreciation	352	366	362	412	417	430	500	530	1,492	1,877	420	
Interest	304	303	283	289	321	340	350	360	1,179	1,371	293	
Other Income	139	182	156	176	351	191	164	185	653	891	149	
PBT before EO expense	1,551	1,975	2,587	2,686	3,184	2,637	3,041	3,225	8,799	12,087	2,634	
Extra-Ord. expense	0	0	205	-137	0	0	0	0	68	0	0	
PBT	1,551	1,975	2,383	2,823	3,184	2,637	3,041	3,225	8,732	12,087	2,634	
Tax	379	491	529	697	751	664	765	812	2,096	2,991	663	
Rate (%)	24.5	24.9	22.2	24.7	23.6	25.2	25.2	25.2	24.0	24.7	25.2	
Reported PAT	1,172	1,484	1,854	2,126	2,433	1,973	2,276	2,414	6,636	9,096	1,984	
Adj. PAT	1,172	1,484	2,008	2,023	2,433	1,973	2,276	2,414	6,686	9,096	1,984	23
YoY Change (%)	128.9	152.2	140.1	112.9	107.6	33.0	13.4	19.3	131.7	36.0	69.3	
Margin (%)	16.2	19.6	22.5	21.6	23.3	19.7	20.1	20.1	20.2	20.8	20.6	

Exhibit 1: One-year forward P/E trend





Exhibit 2: One-year forward P/B trend



Story in charts – 1QFY27

Exhibit 3: Sales increased 44% YoY




Exhibit 4: Margin trend




Exhibit 5: EBITDA rose 80% YoY




Exhibit 6: Adjusted PAT trend




Exhibit 7: Specialty Chemicals revenue increased 48% YoY




Exhibit 8: CDMO revenue increased 61% YoY - CDMO (INR b)




Exhibit 9: HPP sales increased 33% YoY (INR b)





Exhibit 10: Revenue mix for the quarter



Source: Company, MOFSL

Source: Company, MOFSL



Management concall highlights

Specialty Chemicals

- Revenue increased 48% YoY to INR3.3b, with exports at 62%.
- The product pipeline continues to remain strong, with meaningful scale-up across existing molecules and a strong line-up of new launches.
- The Chemours project is targeted for completion by the end of 2QFY27. The scale-up, however, will require some time.
- MPP debottlenecking capacity is on track for commissioning in 3QFY27, with revenue potential of ~INR1.4-1.6b.
- 4-5 new molecules will be pitched in the Spec Chem business in FY27. Three are already patented, and pricing pressure is not likely.

CDMO

- Revenue increased 82% YoY to INR1.8b, with exports at 98%.
- The company continued to deepen its engagement with European CDMO majors, supported by increasing demand for existing molecules and an expanding footprint within their supply chain. It is now pursuing an MSA for an additional molecule in the same supply chain (API minus 1 stage) with an existing customer. It is also working on an early-phase molecule for the same customer.
- BOD initiated phase 2 of cGMP4 capex of INR1.3b (internal accruals) likely to operationalize by 4QFY27, deepening partnership with European majors. The company is targeting Asset T/O of ~3x. Phase 1 was operationalized in 3QFY26, with a capex of ~INR1.6b.
- The company is increasing footprint across a range of promising therapeutic areas with leading global innovators - Oncology, Respiratory, Cardiovascular, Neurology, and Animal Health.
- The company is currently working on 13-14 molecules, of which 10 are in the late stages of development and 3 are expected to receive FDA readouts in the next 8-12 months.

HPP

- Revenue increased 33% YoY to INR5.4b, with exports at 54%.
- Revenue growth was driven by higher realizations and healthy volumes.
- Pricing environment for HFC continues to be constructive, supported by demand-supply dynamics and an increasing interest for contractual offtakes in new capacities.
- The AHF facility commenced operations in 4QFY26 and continues to be ramped up.
- The additional 15k MTPA capacity of R32 is on track and likely to be commissioned in 3QFY27. The project entails a total capex of INR2.4b and is expected to generate revenue of ~INR6-8.3b per annum. The company intends to adopt competitive pricing while benefiting from operational leverage.
- Long-term demand appears constructive for R32; demand is expected to double in a decade with supply being cut half.

- India's R32 market is expected to remain oversupplied, prompting the company to focus on export markets. Customers are seeking long-term contracts (5 years) to secure R32.
- HF ~60k MTPA capacity is good on consol. level for the company.
- The company has signed a 7-year contract relating to HFOs with Honeywell, which had commenced in Aug'22, with a further extendible period of three years.

Advanced materials

- The BOD has approved a capex of INR900m to set up adoption capacities for advanced materials at the Surat unit funded through internal accruals. This facility is expected to be commissioned by 2QFY28.
- 4-5 lab-scale products have already been approved by customers, and the new capacity will enable their transition to commercial-scale qualification.
- The company has partnered with DRDO for indigenous process development of a critical defense material. Currently imported, this chemical is expected to be localized by the company. The application of this product extends beyond defense.
- High-growth, high-margin segments focusing on data centers, semiconductor, electronics, and defense leverage the company's core fluorinated expertise.
- Management highlighted specific applications within this vertical - Chip cooling process and display manufacturing, high-voltage electric applications, and advanced intermediates for films/coatings.
- The vertical is currently being incubated and is likely to evolve into a CDMO-like business in some years.
- Electronic-grade HF will also be part of this vertical once announced by the company.
- This will be reported under the current three verticals, only until it reaches major numbers.

Outlook

- Growth through FY28 is largely baked in by the current capex. Growth factors for further years will be planned ahead as the current capex gets qualified.
- EBITDA margin is guided at ~33% (+/- 2pp) for FY27.

Subsidiary performance

- Since the subsidiary business is campaign-driven, the product mix plays a major role.
- The AHF capacity has been commissioned at the subsidiary, resulting in transfer pricing adjustments.
- The subsidiary is evaluating downstream products, which are expected to improve its margin profile.

Others

- Investment in SPV for setting up a hybrid power plant - Investment of INR157m for 14.9 MW of Hybrid capacity across NFIL and NFASL. More than 60% requirement will be met by this project through renewable sources.
- The company became net debt-free during the quarter.
- Net WC days stood at 81.
- Gross margins contracted sequentially, but operational leverage helped in sustaining margins.
- RM costs are being passed on to customers, wherever possible.

Exhibit 11: Summary of our revised estimates

Particulars	Revised		Previous		Change (%)	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue (INR m)	43,784	52,845	42,341	49,698	3%	6%
EBITDA (INR m)	14,444	16,901	13,482	15,162	7%	11%
PAT (INR m)	9,096	10,618	8,289	9,375	10%	13%
EPS (INR)	177.5	207.2	161.7	182.9	10%	13%

Financials and valuations

Consolidated - Income Statement

	(INR m)							
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	11,331	14,534	20,774	20,650	23,494	33,139	43,784	52,845
Change (%)	10.8	28.3	42.9	-0.6	13.8	41.1	32.1	20.7
Gross Margin (%)	54.9	54.2	56.9	54.7	55.8	58.5	58.1	56.9
EBITDA	3,108	3,548	5,503	3,983	5,337	10,817	14,444	16,901
Margin (%)	27.4	24.4	26.5	19.3	22.7	32.6	33.0	32.0
Depreciation	407	479	626	962	1,194	1,492	1,877	2,210
EBIT	2,702	3,069	4,877	3,021	4,143	9,325	12,568	14,692
Int. and Finance Charges	14	19	275	746	779	1,179	1,371	1,452
Other Income	745	392	357	559	437	653	891	950
PBT bef. EO Exp.	3,433	3,442	4,959	2,834	3,801	8,799	12,087	14,190
EO Items	662	0	0	521	0	-68	0	0
PBT after EO Exp.	4,095	3,442	4,959	3,355	3,801	8,732	12,087	14,190
Total Tax	1,103	812	1,207	650	915	2,096	2,991	3,571
Tax Rate (%)	26.9	23.6	24.3	19.4	24.1	24.0	24.7	25.2
Reported PAT	2,992	2,631	3,752	2,705	2,886	6,635.6	9,096	10,618
Adjusted PAT	2,508	2,631	3,752	2,285	2,886	6,687	9,096	10,618
Change (%)	-37.3	4.9	42.6	-39.1	26.3	131.7	36.0	16.7
Margin (%)	22.1	18.1	18.1	11.1	12.3	20.2	20.8	20.1

Consolidated - Balance Sheet

	(INR m)							
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	99	99	99	99	99	103	103	103
Total Reserves	16,402	18,343	21,750	23,728	26,163	39,643	46,868	55,301
Net Worth	16,501	18,442	21,850	23,827	26,262	39,746	46,970	55,404
Total Loans	0	1,000	8,487	13,399	14,407	12,264	12,877	13,521
Deferred Tax Liabilities	167	201	348	643	754	1,369	1,369	1,369
Capital Employed	16,668	19,644	30,684	37,869	41,424	53,378	61,216	70,293
Gross Block	4,937	5,714	17,629	20,890	30,712	38,089	43,670	52,399
Less: Accum. Deprn.	1,459	1,938	2,565	3,526	4,721	6,213	8,089	10,299
Net Fixed Assets	3,478	3,776	15,065	17,363	25,992	31,877	35,580	42,100
Capital WIP	365	7,421	2,786	7,111	3,498	1,433	4,537	5,157
Total Investments	4,503	1,181	955	5,453	5,293	12,773	12,773	12,773
Curr. Assets, Loans, and Adv.	10,319	11,477	15,610	12,964	12,644	16,832	21,170	26,073
Inventory	1,543	2,575	4,681	3,717	3,224	4,456	5,856	7,175
Account Receivables	2,759	3,577	5,615	5,125	5,824	7,518	9,933	11,988
Cash and Bank Balance	3,889	902	348	276	405	970	1,493	3,023
Loans and Advances	2,128	4,423	4,966	3,847	3,190	3,888	3,888	3,888
Curr. Liability and Prov.	1,998	4,211	4,609	5,900	6,880	10,413	13,722	16,688
Account Payables	1,027	141	2,435	3,025	3,270	5,293	6,956	8,522
Other Current Liabilities	824	3,879	1,944	2,569	3,342	4,956	6,547	7,902
Provisions	147	191	231	306	269	165	218	263
Net Current Assets	8,322	7,266	11,001	7,064	5,764	6,418	7,448	9,386
Appl. of Funds	16,668	19,644	30,684	37,869	41,424	53,378	61,216	70,293

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)								
EPS	50.7	53.1	75.7	46.1	58.2	130.5	177.5	207.2
EPS Growth (%)	-37.3	4.7	42.6	-39.1	26.2	124.2	36.0	16.7
Cash EPS	58.9	62.8	88.4	65.5	82.3	159.6	214.1	250.3
BV/Share	333.5	372.2	441.0	480.9	529.5	775.5	916.5	1,081.1
DPS	11.0	11.0	12.0	15.0	12.0	26.6	36.5	42.6
Payout (%)	18.2	20.7	15.8	27.4	20.6	20.6	20.6	20.6
Valuation (x)								
P/E	150.3	143.5	100.6	165.2	131.0	58.4	42.9	36.8
Cash P/E	129.3	121.4	86.2	116.3	92.6	47.7	35.6	30.4
P/BV	22.8	20.5	17.3	15.8	14.4	9.8	8.3	7.0
EV/Sales	32.9	26.0	18.6	18.9	16.7	12.1	9.2	7.6
EV/EBITDA	120.0	106.4	70.1	98.1	73.4	37.1	27.8	23.7
Dividend Yield (%)	0.1	0.1	0.2	0.2	0.2	0.3	0.5	0.6
FCF per share	52.1	-101.1	-165.3	14.5	0.9	78.9	61.5	88.2
Return Ratios (%)								
RoE	16.5	15.1	18.6	10.0	11.5	20.3	21.0	20.7
RoCE	16.4	14.6	15.7	8.4	8.8	16.0	17.7	17.8
RoIC	25.3	26.0	20.1	9.4	11.0	20.1	23.5	24.0
Working Capital Ratios								
Fixed Asset Turnover (x)	3.2	4.0	2.2	1.3	1.1	1.1	1.3	1.4
Asset Turnover (x)	0.7	0.7	0.7	0.5	0.6	0.6	0.7	0.8
Inventory (Days)	50	65	82	66	50	49	49	50
Debtor (Days)	89	90	99	91	90	83	83	83
Creditor (Days)	33	4	43	53	51	58	58	59
Leverage Ratio (x)								
Current Ratio	5.2	2.7	3.4	2.2	1.8	1.6	1.5	1.6
Net Debt/Equity ratio	-0.2	0.0	0.4	0.6	0.5	0.3	0.2	0.2

Consolidated - Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
(INR m)								
OP/(Loss) before Tax	4,095	3,442	4,959	3,355	3,801	8,732	12,087	14,190
Depreciation	407	479	626	962	1,194	1,492	1,877	2,210
Others	-1,054	-289	184	-86	560	684	1,371	1,452
Direct Taxes Paid	-186	-781	-1,098	-343	-780	-1,591	-2,991	-3,571
(Inc.)/Dec. in WC	-305	-2,104	-5,308	3,611	933	-382	-507	-408
CF from Operations	2,958	748	-636	7,499	5,708	8,936	11,837	13,872
Capex	-382	-5,758	-7,555	-6,783	-5,665	-4,891	-8,684	-9,350
Free Cash Flow	2,576	-5,011	-8,191	717	43	4,044	3,152	4,522
Change in Investments	-914	3,757	799	-4,313	402	-7,628	0	0
CF from Investments	-3,452	-1,724	-6,556	-10,936	-5,110	-12,349	-8,684	-9,350
Inc./(Dec.) in Debt	0	1,020	7,442	4,913	1,014	-2,140	613	644
Interest Paid	-14	-19	-275	-746	-786	-1,056	-1,371	-1,452
Dividend Paid	-394	-542	-543	-743	-595	-680	-1,871	-2,185
CF from Fin. Activity	-437	415	6,579	3,358	-467	3,442	-2,627	-2,993
Inc./Dec. in Cash	-931	-561	-613	-78	131	29	525	1,529
Opening Balance	1,692	760	758	144	66	197	226	750
Closing Balance	760	758	144	66	197	226	750	2,279

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$-10\% \text{ to } 15\%$
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.